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Abstract
Insulin and insulin-like growth factors (IGFs) maintain vital neuronal functions. Absolute or
functional deficiencies of insulin or IGF-I may contribute to neuronal and vascular complications
associated with diabetes. Vanilloid receptor 1 (also called TRPV1) is an ion channel that mediates
inflammatory thermal nociception and is present on sensory neurons. Here we demonstrate that
both insulin and IGF-I enhance TRPV1-mediated membrane currents in heterologous expression
systems and cultured dorsal root ganglion neurons. Enhancement of membrane current results
from both increased sensitivity of the receptor and translocation of TRPV1 from cytosol to plasma
membrane. Receptor tyrosine kinases trigger a signaling cascade leading to activation of
phosphatidylinositol 3-kinase (PI(3)K) and protein kinase C (PKC)-mediated phosphorylation of
TRPV1, which is found to be essential for the potentiation. These findings establish a link between
the insulin family of trophic factors and vanilloid receptors.
Introduction
TRPV1 is a Ca2+ permeable nonspecific cation channel,
located on peripheral sensory neurons, that serves as a
molecular detector for heat, capsaicin, protons, and
endovanilloids [1-4]. Moreover, its role as a heat sensor
(activation threshold of ~43°C), its influence from
trophic/inflammatory agents (i.e. nerve growth factor,
bradykinin, prostaglandins, etc.) and its vasodilatory
effect on small vessels (by releasing CGRP) make TRPV1
an essential component of the pain pathway [3,5-11].
In peripheral nerves, insulin does not promote its typical
metabolic effects of glucose and amino acid uptake [12].
However, physiologic concentrations can act as neuro-
trophic factors, in combination with nerve growth factor
(NGF), to stimulate neurite outgrowth and survival of
both sensory and sympathetic neurons [13-15]. Further-
more, it has been proposed that insulin and IGFs exert
trophic influences on the same neurons that are respon-
sive to NGF by sharing common signaling pathways [13].
Though it is widely believed these neural disturbances are
secondary to hyperglycemia [16], this remains controver-
sial. Results from the Diabetes Control and Complica-
tions Trial show that intensive glycemic control for 5 years
reduced the incidence of neuropathy by 60% in Type I
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patients [17]. However, the fact that strict glucose regula-
tion does not completely prevent diabetic peripheral neu-
ropathy suggests additional mechanisms as a result of
insulin deficiency may be involved.
Experiments in humans show that non-diabetic, normo-
glycemic subjects have heat thresholds that correlate pos-
itively with insulin sensitivity [18]. Furthermore,
circulating levels of IGFs and NGF are reduced in diabetes
and to a greater degree in patients with thermal sensory
deficits characteristic of neuropathy [19-21]. Growth fac-
tor replacement therapy improves neuronal regeneration
[22,23] and insulin, under conditions of rapid infusion,
can restore decreased neurogenic vasodilation [24,25].
Taken together, these studies suggest that insulin and
trophic factor deficiencies may alter sensory nerve func-
tion [26].
In this study we demonstrate that insulin and IGF-I
enhance TRPV1-mediated membrane currents by enhanc-
ing receptor sensitivity and translocation from cytosol to
plasma membrane in heterologous expression systems
and cultured dorsal root ganglion (DRG) neurons in a
PKC-dependent manner. Preliminary results of this study
have been published elsewhere in an abstract form [27].
Materials and Methods
Oocyte Electrophysiology
Oocytes were isolated from tricaine-anesthetized Xenopus
laevis and separated from the follicular layer after incuba-
tion with collagenase (1–2 mg/ml). 3–7 days following
cRNA injections (50–70 nl, 1 µg/µl), oocytes were stored
at 18°C and used for experiments. Double electrode volt-
age clamp (-60 mV) was performed using a Warner ampli-
fier (Warner Instruments, OC725C, Hamden, CT, USA)
with 100% d.c. gain, digitized and stored on video tape.
Experiments were performed at 21–23°C. Oocytes were
placed in a Perspex chamber superfused (5–10 ml min-1)
with Ca2+-free Ringer solution containing (in mM): 100
NaCl, 2.5 KCl, 5 HEPES, pH 7.35. Within figures, current
traces were shown as initial response to agonist juxta-
posed on currents recorded following incubation with
insulin, IGF-I and various inhibitors. Time course experi-
ments consisted of current recording during capsaicin
application in the presence of either control (first 20 min)
or insulin (last 15 min) containing solutions. In all exper-
iments, fold increase was calculated as agonist induced
current amplitude in the presence of trophic factors and
inhibitors divided by the agonist induced initial current
amplitude under control conditions before their bath
application. I-V relationships were measured using 500-
ms voltage ramps from -80 mV to +80 mV.
DRG Culture and Electrophysiology
Dorsal root ganglia were isolated from embryonic day 18
(E18) rats, triturated and cultured for 5–7 d in Neuroba-
sal/B-27 (Life Technologies; Grand Island, NY) + 10%
fetal bovine serum (FBS) on poly-D-lysine-coated glass
coverslips. For perforated patch recording, the bath solu-
tion contained (in mM): 140 NaGlu, 2.5 KCl, 10 HEPES,
2 MgCl2, 1 EGTA, pH 7.35 and the pipette solution con-
tained (in mM): 130 NaGlu, 10 NaCl, 2.5 KCl, 10 HEPES,
1 MgCl2, 0.2 EGTA, and amphotericin B (240 µg/ml). For
cell-attached recording, the bath solution contained (in
mM): 140 Kglu, 10 NaCl, 10 HEPES, 1 EGTA, 2 MgCl2, pH
7.35 and the pipette contained (in mM): 140 NaGlu, 2.5
KCl, 10 HEPES, 2 MgCl2, pH 7.35. Currents were recorded
using a WPC 100 patch clamp amplifier (E. S. F. Elec-
tronic, Goettingan, Germany) or Axopatch 200B (Axon
Instruments, Union City, CA). Data were digitized (VR-
10B, Instrutech Corp.; Great Neck, NY) and stored on
video tape.
For analysis, data were filtered at 2.5 kHz (-3db frequency
with an 8-pole low-pass Bessel filter, Warner Instruments,
LPF-8) and digitized at 5 kHz. Data analyses were per-
formed on continuous stretches greater than 20 s from
patches that contained one or two channels. Single chan-
nel current amplitude and Po were calculated from all
point amplitude histograms fitted with Gaussian func-
tions (Microcal Origin; Northampton, MA).
Ca2+ Imaging
Cells were grown on glass coverslips, then incubated with
5 µM Fluo-4AM (Molecular Probes; Eugene, OR) for 20
min at 37°C, washed with physiological buffer [(in mM):
140 NaCl, 5 HEPES, 2 CaCl2, 1 MgCl2, 2.5 KCl, pH 7.35],
and treated with 500 nM capsaicin +/- 1 µM insulin
immediately prior to analysis by confocal microscopy
(Fluoview, Olympus; Mellville, NY). Data for each cell
was quantified as the fluorescence after treatment (F)
divided by initial fluorescence (Fo) at t = 0 (Fluoview
software).
Transfection of Cells and Cell Culture
HEK 293 cells, which endogenously express IGF-I recep-
tors [29] were cultured in Dulbecco's modified Eagle's
medium (high glucose) supplemented with 10% fetal
bovine serum, 50 units/ml penicillin, and 50 µg/ml strep-
tomycin (Invitrogen; Carlsbad, CA) and maintained
under 95% air/ 5% CO2 at 37°C. Cells were transiently
transfected with wild type TRPV1, TRPV1eGFP, TRPV1
S502/S800A mutant (gifted by D. Julius, N. Kadei, M.
Tominaga, respectively), or TRPV1-V5-His tagged plasmid
using Lipofectamine2000 reagent (Invitrogen) according
to manufacturer's protocol. TRPV1-V5-His tagged plasmid
was constructed in pcDNA3.1 vector using Topo Cloning
kit (Invitrogen). To determine the membraneMolecular Pain 2005, 1:17 http://www.molecularpain.com/content/1/1/17
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translocation of TRPV1, confocal images (1 µm sections)
of GFP-tagged TRPV1 fluorescence was obtained. The
intensity of the brightest membrane fluorescence was
selected and quantified using MCID imaging software
(Imaging Research Inc; St. Catherines, ONT)
Determination of Surface TRPV1
After 36 h of TRPV1 transfection, the cells (grown on 100
mm tissue culture plate) were insulin-treated and bioti-
nylated with membrane impermeable NHS-LC-biotin
(1.5 mg/ml in PBS; Pierce, Rockford, IL) as per manufac-
turer's protocol. Labeled cells were lysed in RIPA buffer
and immunoprecipitated overnight with 10 µl of goat
anti-VR1 polyclonal antibody/ Protein A/G Plus-agarose
(Santa Cruz Biotechnology, Santa Cruz, CA) following
manufacturer's protocol. Immunoprecipitates were eluted
with 2X SDS sample buffer, separated on 7.5% SDS-
PAGE, and transferred to PVDF membrane. To detect total
TRPV1, blots were probed with rabbit anti-VR1 polyclonal
antibody (1:1000; Affinity Bioreagents, Golden, CO).
Specific antibody binding was detected using HRP-conju-
gated anti-rabbit secondary antibody (1:20,000; Jackson
Immunoresearch, West Grove, PA) and Super Signal rea-
gent (Pierce). To detect surface TRPV1, blots were stripped
and probed with neutravidin-HRP (1:20,000; Pierce).
Chemiluminescence was captured in Hitachi CCD Bio
Genetic Systems after exposing the blot to Super Signal
reagent (Pierce). Data were quantitated using LabWorks
analysis software (UVP Inc., Upland, CA) and surface
TRPV1 was normalized using total TRPV1. TRPV1-V5-His
transfected cells were biotinylated as above and purified
using Ni-NTA agarose (Qiagen, Valencia, CA) as per man-
ufacturer's protocol.
Immunohistochemistry
Cells were plated on glass coverslips coated with 40 µg ml-
1 poly-L-lysine, treated with insulin/IGF/PDBu after 36 h
of transfection, and fixed with 4% paraformaldehyde for
1 h. The cells were probed with rabbit anti-VR1 antibody
(1:10,000; Affinity Bioreagents) followed by rhodamine
red-X conjugated anti-rabbit secondary antibody (1:50;
Jackson Immuno Research) following method described
by Santa Cruz Biotechnology. Confocal images (1 µm sec-
tions) were captured using 570 nm laser. The brightest
membrane fluorescence was selected from control and
treated cells and quantified using MCID imaging software
(Imaging Research Inc.).
Unless otherwise stated, all chemicals were obtained by
Sigma (St. Louis, MO). Data are given as mean ± s.e.m.
and statistical significance (set at P < .05) was evaluated
using Student's t-test or one-way ANOVA.
Results
Insulin and IGF-I potentiate TRPV1 current in oocytes
First, we tested whether insulin and/or IGFs influence
TRPV1-mediated membrane currents. The effect of insulin
and IGF-I on cloned TRPV1 was characterized through
dual-electrode voltage clamp (Vm = -60 mV) of Xenopus
oocytes injected with TRPV1 cRNA. Insulin (1 µM) signif-
icantly potentiated the response to capsaicin (500 nM)
greater than 2 fold (Fig. 1a). The time course of insulin-
induced potentiation of capsaicin response shows a signif-
icant increase in current amplitude for 5, 10 and 15
minute incubation periods compared to initial levels (Fig.
1b). Dose response curves of capsaicin show that both the
sensitivity (EC50 shifted from 0.9 to 0.6 µM) and the max-
imal response (normalized to 1 µM capsaicin induced cur-
rent before insulin application) increased (from 1.8 to
2.4) after incubation of oocytes with insulin (circles) for 5
min (Fig. 1c). A representative current-voltage relation-
ship (I-V curve) confirms the outward rectification charac-
teristic of TRPV1 current and shows that, in the presence
of insulin, amplitude is increased at both positive and
negative potentials (Fig. 1d). In addition, current potenti-
ation was also seen with heat evoked responses (Fig. 1e)
and protons (Fig. 1f), an endogenous TRPV1 agonist.
These experiments show that insulin is increasing TRPV1-
mediated currents and making the receptor more respon-
sive to exogenous and endogenous activators.
Oocytes endogenously express insulin-like growth factor
receptors (IGFR) rather than insulin receptors (IR) [30].
Insulin binds to IGFR with 100–1000 times lower affinity
than IR. On the other hand, IGF-I binds to IGFR with
much higher affinity, so we tested whether lower concen-
trations of IGF-I could potentiate TRPV1. Indeed, 20 nM
IGF-I potentiated pH currents to a similar degree as 1 µM
insulin (Fig. 1g). Potentiation was dramatically reduced
by the addition of tyrphostin A47 (100 µM; 10 min), a
selective inhibitor for the insulin family of receptor tyro-
sine kinases (Fig. 1h). Together these data suggest that in
oocytes, insulin and IGF-I are acting through IGFR to
potentiate TRPV1 (Fig. 1i).
Insulin and IGF-I potentiate native TRPV1 current in DRG 
neurons
Since insulin and IGF-I functions vary with cell type, it was
important to establish that current potentiation also
occurred in sensory neurons that express native TRPV1
[15,21]. Therefore, we determined the effect of insulin
and IGF-I on capsaicin-induced TRPV1 responses using
cultured DRG neurons. For whole cell recordings, the per-
forated patch technique was used to prevent desensitiza-
tion and tachyphylaxis, minimize intracellular disruption,
and maintain intact signaling cascades. In this setting,
insulin (1 µM) induced a potentiation of the capsaicin
(100 nM) response (Fig. 2a), which returned to controlMolecular Pain 2005, 1:17 http://www.molecularpain.com/content/1/1/17
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levels 20 minutes after its removal (Fig. 2b, inset). Like
oocytes, similar results were seen with IGF-I, signifying
that insulin was binding IGFR in DRG neurons (Fig. 2c).
To confirm electrophysiological experiments, measure-
ments of Ca2+-uptake were performed using confocal
microscopy (Fig. 2d). In DRG neurons, capsaicin (500
nM) produced a Ca2+ influx that was increased in the pres-
ence of insulin. This shows that insulin elevated TRPV1-
regulated Ca2+ mobilization. Together this data, confirm
that the potentiation seen with cloned TRPV1 in oocytes
Insulin and IGF-I potentiate TRPV1 currents in Xenopus Oocytes Figure 1
Insulin and IGF-I potentiate TRPV1 currents in Xenopus Oocytes. a, A representative dual-electrode whole-oocyte experiment 
showing potentiation of capsaicin induced TRPV1 currents following 15 min incubation of insulin (see Methods). b, Time 
course for capsaicin induced current (■ : 500 nM capsaicin, 30 sec application) before and after insulin exposure at 5 (P < .05), 
10 (P < .01), and 15 min (P < .01) incubation times (n = 7). c, Dose response curve of capsaicin before (squares) and after 5 µM 
insulin (circles) application, the currents were normalized to 1 µM capsaicin before insulin application (n = 2 to 4, before and 
after insulin). Both the sensitivity (EC50 shifted from 0.9 to 0.6 µM) and maximal response increased (1.8 to 2.4). d, Represent-
ative I-V relationships (1 s, 1 mV step ramp from -80 to +80 mV) before and after insulin treatment that demonstrates the out-
ward rectification typical of TRPV1 channels. e, Potentiation of heat-induced currents by insulin. f, Potentiation of pH induced 
currents by insulin. g, Potentiation of pH induced currents by IGF-I. h, Tyrphostin A47, an IR / IGFR antagonist, blocked insulin 
potentiation. i, Summary graph showing fold increase in TRPV1 currents following 10 min incubation with control, insulin (cap: 
n = 5, P < .01; pH: n = 4, P < .01), IGF-I (n = 3, P < .01), and insulin + tyrophostin A47 (n = 3, P < .01). Results are expressed as 
increase in current amplitude relative to initial capsaicin or pH response.
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is present in native TRPV1 expressing peripheral sensory
neurons as well.
Insulin increases single channel activity
To understand the underlying molecular mechanism
responsible for whole-cell potentiation, single channel
currents were recorded in cell-attached patches from DRG
neurons. Under this configuration, extracellular insulin
would require receptor mediated signal transduction to
facilitate changes in TRPV1 channel function recorded
within the patch area (Fig. 2e). Channel open probability
(Po), a measure of the time the channel spends in the
open state, induced by capsaicin (10 nM) increased fol-
lowing bath-application of insulin (1 µM), outside the
patch area (Fig. 2e, lower graphs). Po significantly changed
from 0.15 ± 0.05 in control conditions to 0.43 ± 0.14 after
insulin (Fig. 2f), without altering the single channel
amplitude (Fig. 2g). Since insulin application was outside
Insulin and IGF-I potentiate native TRPV1 currents in DRG neurons Figure 2
Insulin and IGF-I potentiate native TRPV1 currents in DRG neurons. a, Capsaicin (100 nM, applied at 2 min intervals) response 
was enhanced by insulin (1 µM) under perforated patch conditions. b, Time course of insulin induced potentiation of capsaicin 
currents (■ : 500 nM capsaicin, 20 sec application) (n = 4, P < .01 at 5, 10, and 15 min incubation times). Inset shows the time 
course for experiment in Fig. 2a. c, Summary graph showing fold increase in TRPV1 currents following 10 min treatment with 
control (n = 15), insulin (1 µM; n = 11, P < .01) and IGF-I (20 nM; n = 4, P < .01). d, Under confocal microscopy, insulin (1 µM, 
2 min) potentiated intracellular Ca2+ rise in response to 500 nM capsaicin (n = 10, P < .05). e, Capsaicin induced single channel 
current activity recorded at +60 mV was increased by exposure of cell to insulin (1 µM). f, Mean capsaicin induced open prob-
ability (Po) in the absence and presence of insulin (n = 5, P < .05). g, Mean current amplitude observed from single channel 
recordings (n = 5).
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the patch, these data support intracellular signaling, as
opposed to direct binding to TRPV1 as a mechanism for
insulin-mediated potentiation.
Signaling cascades utilized by Insulin and IGF-I
IR and IGFR produce their effects via an overlapping set of
downstream enzymes [29], so we sought to identify sign-
aling pathways involved in TRPV1 modulation. First,
receptor tyrosine kinase (RTK) involvement was assessed
by pretreating oocytes with membrane permeable inhibi-
tors before and during insulin application (Fig. 3a). The
nonspecific RTK blockers genistein (50 µM, 60 min) and
lavendustin A (100 µM, 60 min) significantly reduced
IGF-I (20 nM, 10 min) potentiation. Second, wortmannin
(100 nM, 15 min), a specific phosphatidylinositol 3-
kinase (PI(3)K) inhibitor, reduced potentiation as well.
Thus, we reasoned that insulin and IGF-I utilize receptor
tyrosine kinases to activate PI(3)K and prompt a signaling
cascade that leads to TRPV1 current potentiation.
PI(3)K mediates some of its effects through various iso-
forms of protein kinase C (PKC) [29]. Therefore, we tested
in oocytes expressing TRPV1 whether insulin and IGF-I
could activate PKC, an enzyme known to potentiate
TRPV1 through channel phosphorylation [8,31]. Bisin-
doylmaleimide (BIM; 200 nM, 60 min), a nonspecific
PKC inhibitor, significantly decreased IGF-I potentiation
(Fig. 3a). The importance of PKC was further demon-
strated using a mutant TRPV1 (S502A/S800A), which
lacks residues acting as substrates for PKC phosphoryla-
tion (31) (Fig. 3b, upper trace). Two consequences of
these mutations were apparent. First, insulin/IGF-I poten-
tiation was abolished. Second, current amplitude was
smaller in oocytes injected with mutant TRPV1 compared
to wild type, suggesting that phosphorylation might have
an intrinsic effect on basal channel function. Thus, it
appears that RTK, PI(3)K and PKC activation are required
for current potentiation by insulin.
Insulin and IGF-I translocate TRPV1 to the plasma 
membrane
In a number of systems, insulin and/or IGF-I can increase
surface content of effector molecules [32-34]. We have
used five different approaches to examine whether TRPV1
translocation occurs in response to insulin or IGF-I. First,
we used cytochalasin D (1 µM, 60 min) to inhibit actin
polymerization and decrease vesicular fusion to the
plasma membrane in oocytes (Fig. 3b, lower traces). Cyto-
chalasin D almost completely blocked TRPV1 current
potentiation by insulin, implicating involvement of pro-
tein trafficking affecting translocation of both TRPV1 and
PKC. Second, insulin and PDBu not only increased the
potency but also the efficacy of capsaicin induced cur-
rents. In DRG neurons, at saturating concentrations of
capsaicin (20 µM) (Fig. 4ai) the current amplitude
increased (>50%) following exposure (2–5 min) to insu-
lin (1 µM) (Fig. 4aii) or PDBu (1 µM) (Fig. 4aiii) suggesting
recruitment of new channels into the plasma membrane
or activation of previously silent channels (see also Fig.
1c). Third, Western blot analysis of cell-surface bioti-
nylated TRPV1 expressed in HEK cells was carried out to
test whether TRPV1 itself was being translocated to the
plasma membrane (Fig. 4b). Analysis of band densities
indicates that insulin (10 µM, 15 min) doubled surface
TRPV1 expression levels relative to controls. Fourth, rela-
tive surface to cytosol optical intensities were quantified
by immunofluorescence microscopy (Fig. 4c). These
results, obtained with antibodies specific for TRPV1, show
that IGF-I (20 nM, 15 min), insulin (10 µM, 15 min) and
PDBu (10 µM, 15 min), all significantly increased surface
TRPV1 expressed in HEK cells (Fig. 4c). Fifth, similar
results were seen in HEK cells transiently transfected with
green fluorescence protein (GFP)-tagged TRPV1. Exposure
of IGF-I (50 nM) significantly increased the fluorescence
intensity of the membrane within five minutes, indicating
the accumulation of TRPV1 on the membrane (Fig. 4d).
Together, these data suggest the involvement of receptor
translocation in TRPV1 current potentiation and show
that, in the presence of insulin, TRPV1 is mobilized to the
plasma membrane from the cytosol.
Discussion
From these results, we propose that insulin and its related
growth factors provide both trophic and sensory support
to peripheral nerve endings. Insulin and IGF-I can directly
influence nociceptive ion channel function through phos-
phorylation and receptor translocation. In the presence of
these modulators, TRPV1 is more responsive to painful
stimuli (capsaicin, pH and heat) by increasing sensitivity
and lowering thresholds. Based on this evidence, we con-
clude that insulin/IGF levels maintain TRPV1 function
and their deficiency or resistance leads to deficits in
inflammatory thermal sensation. The role of TRPV1 in
animal models of diabetes has been suggested [27,35-37].
The intriguing aspect is that insulin deficiency results in
thermal hyperalgesia in streptozotocin induced diabetes.
Sensitization of TRPV1 by phosphorylation could account
for the hyperalgesic phenotype seen in this animal model
of diabetes [35]. The exact mechanism of sensitization of
TRPV1 is not clear, but could be due to over compensa-
tion by other tropic factors, such as NGF in response to
insulin deficiency or elevated PKC activity in diabetes
[38].
Using multiple methods, we elucidate molecular mecha-
nism(s) by which insulin/IGF-I potentiate TRPV1 current
(Fig. 3 and 4). These neurotrophic factors, operating
through RTKs, trigger a signaling cascade leading to
PI(3)K and PKC activation [27,28,35]. PKC, an enzyme
known to sensitize TRPV1 through phosphorylationMolecular Pain 2005, 1:17 http://www.molecularpain.com/content/1/1/17
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Singnaling cascades utilized by Insulin and IGF-I Figure 3
Singnaling cascades utilized by Insulin and IGF-I. a, Summary graph showing fold increase of current in the presence of IGF-I and 
the inhibitors: genistein (50 µM, n = 6, P < .05), lavendustin A (100 µM, n = 7, P < .05), wortmannin (100 nM, n = 5, P < .05) and 
BIM (200 nM, n = 5, P < .05). b, A PKC phosphorylation site TRPV1 mutant (S502A/S800A) (n = 6, P < .01, upper trace) and 
cytochalasin D (1 µM, n = 4, P < .01, lower trace) completely blocked insulin potentiation.
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[5,8,31], increases channel activity and receptor transloca-
tion to the cell surface [39]. Activation of a similar path-
way to insulin by NGF via PI(3)K has been shown to
robustly potentiate TRPV1 current [40]. Since insulin/IGF-
I levels and PKC activity are altered in diabetes, we specu-
late that abnormalities in TRPV1 function may contribute
to neuropathy in diabetes.
In DRG sensory neurons, diminished growth factor levels
are some of the earliest changes noticed with diabetic neu-
Insulin and IGF-I translocate TRPV1 to the plasma membrane Figure 4
Insulin and IGF-I translocate TRPV1 to the plasma membrane. a, Potentiation of saturating concentrations of capsaicin 
response by insulin and PDBu. Application of 5, 10 and 20 µM capsaicin shows saturation of current response (ai), exposure 
(2–5 min) of insulin (aii) or PDBu (aiii) caused a 50% increase in current amplitude induced by 20 µM capsaicin (aiv) (insulin n = 
4 P < .01; PDBu n = 5 P > .01). b, Representative Western blot of surface protein and total TRPV1 from control and insulin-
treated (10 µM, 15 min) HEK293 cells expressing TRPV1 (probed with anti-TRPV1 antibody). Surface represents fraction of 
biotinylated TRPV1 and total represents total amount of TRPV1 in immunoprecipitate. Quantitative analysis of insulin's effect 
on surface expression, with mean densities of surface bands normalized to control values for samples run on the same gel (n = 
4, P < .01). c, Immunohistochemistry performed TRPV1 transfected HEK cells that were exposed to IGF-I (20 nM, 15 min), 
insulin (10 µM, 15 min) and PKC agonist, PDBu (10 µM, 15 min). Quantification of relative optical intensities (ROI, normalized 
as surface/cytosol for each cell): (control: n = 5; IGF-I: n = 7, P < .05; insulin: n = 3 P < .01; and PDBu: n = 7, P < .01). d, Confo-
cal image showing a significant increase (3.17 ± 0.52 fold, n = 9; P < .01) in fluorescence intensity at the membrane 5 min after 
exposure to IGF-1 (50 nM) in HEK cells heterologously expressing GFP-TRPV1 fusion protein as compared to before IGF-1 
application.
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ropathy [11,20,21]. One explanation for diabetic neurop-
athy states that it is, in essence, a microvascular
disturbance [41]. Peripheral C fibers (which express
TRPV1) release vasoactive substances like CGRP, causing
small vessel dilation to increase cutaneous circulation and
nerve terminal viability. Activation of TRPV1 has been
shown to induce and enhance the release of CGRP (7).
This neural component of microcirculatory control is
decreased in diabetic neuropathy, and the consequent
reduction in local blood flow contributes to peripheral
vascular complications [41,42]. With regards to growth
factor deficiency, insulin has a vasodilatory effect that is
dependent on CGRP release, which is compromised in
diabetes [43,44]. Our findings illustrates insulin/IGFs can
cause vasodilation via their influence on TRPV1.
A concept is emerging where signals emanating from IR
and/or IGFR can activate kinases with the potential to
control ion channel phosphorylation, subcellular locali-
zation and overall expression. Our work elucidates the
mechanism insulin/IGF-I use for TRPV1 sensitization (i.e.
RTK→ PI(3)K→ PKC), but the transduction pathway regu-
lating expression has not been identified. Previously, it
was suggested that insulin exerts influences on the same
neurons that are responsive to NGF by sharing common
pathways [13]. Recent reports demonstrate that NGF and
glial cell line-derived neurotrophic factor (GDNF) upreg-
ulate TRPV1 expression on DRG neurons using transduc-
tion mechanisms common to insulin/IGF-I (i.e. MAPKs,
PI(3)K, Ras, etc.) [11,40,45,46]. Taken together, these
studies set precedence for growth factor influence on noci-
ceptor levels and implicate signaling cascades, which may
be compromised by the absence of insulin/IGF.
Insulin potentiates both whole cell and single channel
currents mediated by NMDA receptors in Xenopus oocytes
in a PKC-dependent manner [47]. Moreover, this effect
was found to be due to membrane translocation involving
both PI(3)K and PKC [33,34,38]. In DRG neurons insulin
increased capsaicin induced cobalt uptake [48]. Along
these same lines, insulin can potentiate currents in
HEK293 cells through recruitment of GABAA receptors to
postsynaptic domains [32]. In cultured cerebellar granular
cells, IGF-I potentiates kinate receptors through a PI(3)K
dependent mechanism [49].
Furthermore, vanilloid receptors (VRs) are present
throughout the body, widely believed to have functions
other than temperature sensation. TRPV1 expressed in the
central terminals of the sensory neurons robustly modify
synaptic transmission [50,51]. TRPV1 could be detected
using RT-PCR technique throughout the neuroaxis [52]
and identification of specific ligands such as NADA in cer-
tain brain regions confirms a role in the CNS [53]. The
nature of the receptors involved in this response and their
role in the CNS are not clearly understood, but suggestive
of a direct or indirect role in modifying neurotransmitter
release [54]. TRPV1 is also located in vasculature, bronchi
and urinary bladder [7,55,56]. Modulation of these recep-
tors by lack of insulin and IGF-I may contribute to CNS
disturbances, cardiovascular, respiratory and urinary com-
plications resulting from diabetes.
Lastly, these findings emphasize the importance of main-
taining proper insulin levels and suggest a potential bene-
fit of IGF-I administration in the treatment and
prevention of diabetic complications. We propose that
insulin and IGF-I therapy, partially working through
TRPV1, can improve complications associated with diabe-
tes mellitus.
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